Until dispensed to the patients, these supplies will be stored in a securely locked area, accessible to authorized personnel only. 5.4.2. Test Article Accountability The investigator or designee will maintain accurate records of receipt for all study treatment, including dates and quantities of study drug(s) received . The study treatment will be used in accordance with the protocol by patients who are under the direct supervision of the investigator. The study treatment will be dispensed only by an appropriately qualified person to patients in the study. Accurate records will be kept regarding when, how much, and to whom study treatment is dispensed and administered (patient-by-patient, dose-specific accounting). Reasons for departure from the expected dispensing regimen, including study treatment lost or accidentally or deliberately destroyed, will be recorded. The investigator or designee wil l retain all used, unused, or expired study supplies until the study monitor has SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 168 confirmed the accountability data and the sponsor has approved return or destruction. All clinical study treatments and/or supplies will either be destroyed by the site per institutional policy, or be returned to SELLAS or its designee for destruction per applicable regulations . 5.4.3. Other Supplies Additional supplies provided for this study will be described in the study pharmacy manual. 5.4.4. Blinding This is an open-label study. 5.4.5. Breaking the Blind Not applicable.